Lupin Gets US FDA Approval for Generic Risperidone

Lupin, a pharmaceutical company, has received approval from the US FDA to sell a generic version of risperidone.

This medicine is an extended-release injectable suspension, meaning it's given as a shot that slowly releases the drug.

The shot is used to treat schizophrenia and bipolar disorder.

Lupin used technology from its subsidiary, Nanomi, to create this medicine.

This is the first product using Nanomi's technology and is expected to generate $190 million in annual sales in the US.

This will allow more access to this medicine.